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Abstract
Background: The functional polymorphism -260 C>T in the LPS sensing TLR4 co-receptor CD14 gene enhances
the transcriptional activity and results in a higher CD14 receptor density. Individuals carrying the T/T genotype
also have significantly higher serum levels of soluble CD14. The T allele of this polymorphism has recently been
linked to Chlamydia pneumoniae infection. We investigated the role of the CD14 -260 C>T polymorphism in the
susceptibility to and severity (defined as subfertility and/or tubal pathology) of C. trachomatis infection in Dutch
Caucasian women.
Methods: The different CD14 -260 C>T genotypes were assessed by PCR-based RFLP analysis in three cohorts:
1) A cohort (n = 576) of women attending a STD clinic, 2) a cohort (n = 253) of women with subfertility, and 3)
an ethnically matched control cohort (n = 170). The following variables were used in the analysis: In cohort 1 the
CT-DNA status, CT IgG serology status, self-reported symptoms and in cohort 2, the CT IgG serology status and
the tubal status at laparoscopy.
Results: In the control cohort the CC, CT and TT genotype distribution was: 28.2%, 48.2%, and 23.5%
respectively. No differences were found in the overall prevalence of CD14 -260 genotypes (28.1%, 50.7%, and
21.2%) in cohort 1 when compared to the control cohort. Also no differences were observed in women with or
without CT-DNA, with or without serological CT responses, with or without symptoms, or in combinations of
these three variables. In subfertile women with tubal pathology (cohort 2, n = 50) the genotype distribution was
28.0%, 48.0%, and 24.0% and in subfertile women without tubal pathology (n = 203), 27.6%, 49.3% and 23.2%. The
genotype distribution was unchanged when CT IgG status was introduced in the analyses.
Conclusion: The CD14 -260 C>T genotype distributions were identical in all three cohorts, showing that this
polymorphism is not involved in the susceptibility to or severity of sequelae of C. trachomatis infection.
Published: 20 December 2005
BMC Infectious Diseases 2005, 5:114 doi:10.1186/1471-2334-5-114
Received: 14 August 2005
Accepted: 20 December 2005
This article is available from: http://www.biomedcentral.com/1471-2334/5/114
© 2005 Ouburg et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases 2005, 5:114 http://www.biomedcentral.com/1471-2334/5/114Background
Chlamydia species are related to a broad clinical spectrum
of human disease including Chlamydia pneumoniae in lung
and cardiovascular disease, C. psittaci in pulmonary
emphysema and psittacosis, and C. trachomatis in ocular
and urogenital infections [1-3].
C. trachomatis is the most prevalent sexually transmitted
disease in Europe and the USA. Due to the mostly asymp-
tomatic course of infection, these women will most likely
not be treated resulting in an enhanced risk for the devel-
opment of late complications, which include pelvic
inflammatory disease (PID), ectopic pregnancy and tubal
infertility.
The female reproductive tract is a very complex system
where many factors, including hormones, vaginal flora
and immune mediators, combine to provide protection
on the one hand, while on the other hand maintaining an
environment suitable for conception [4]. Clear differences
in the clinical course of infection have been described and
are due to an interaction between environmental (e.g. co-
infection), bacterial (e.g. virulence factors) and host fac-
tors (genetic differences between individuals). In previous
studies no clear associations have been demonstrated
between C. trachomatis serotype, C. trachomatis genotype,
and the course of C. trachomatis infection[5,6], although
differences in cytotoxicity for different serovars have been
described[7] and an association between C. trachomatis
serovar G and cervical squamous cell carcinoma has been
suggested [8]. In addition, virulence gene expression stud-
ies, and genomic comparisons of strains, isolated from
clearly symptomatic or asymptomatic infected persons,
CD14 localisationFigure 1
CD14 localisation. Panel A: Membrane-bound CD14 (mCD14) complexed with TLR4 and the LBP – LPS complex. Panel B: 
Soluble CD14 (sCD14). Abbreviations: TLR: Toll-Like Receptor; LBP: LPS Binding Protein; LPS: Lipopolysaccharide; NF-κB: 
Nuclear Factor κB.Page 2 of 9
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the course of infection[9,10].
A limited number of studies have recently demonstrated
the influence of host genetic factors on the susceptibility
to and the severity of C. trachomatis infection. Host factors
including HLA-DQ and interleukin 10 (IL-10) have been
associated with Chlamydia infection[11].
The Toll Like Receptor (TLR) family is a group of pattern
recognition receptors, which recognise several microbial
products, including bacterial cell wall components and
DNA[12]. Poltorak et al. associated TLR4 with lipopoly-
saccharide (LPS) recognition in mice[13]. Further studies
in mice corroborated these data [14,15], while studies in
human demonstrated associations between TLR4 muta-
tions and LPS hyporesponsiveness[16]. We did not
observe an association between the TLR4 Asp299Gly pol-
ymorphism in patients with tubal pathology although the
study population was relatively small[17]. The lack of
association can be explained by recent publications show-
ing that heterozygous carriage of the TLR4 Asp299Gly
mutation does not affect LPS responsiveness and that only
the rare homozygous carriers are less responsive to
LPS[18].
CD14 acts as a co-receptor for TLR4 and confers respon-
siveness to LPS, a component of the cell wall of most
Gram-negative bacteria. CD14 forms a complex with LPS
and the LPS-binding protein (LBP) (figure 1) [19]. Com-
bined with TLR4 this complex induces NF-κB associated
immune responses including the release of a broad spec-
trum of cytokines that include tumour necrosis factor
alpha (TNF-α), IL-1, IL-6, and IL-8 to initiate immune
response[20].
The promotor region of the CD14 gene contains a single
nucleotide polymorphism (SNP) at position -260. The -
260 C>T genetic variation affects the binding of transcrip-
tion factors[21] and has been associated with levels of
sCD14 and inversely associated with serum IgE levels[20].
This SNP has been associated with myocardial infarction
[22], Crohn's disease[23] and an increased susceptibility
to develop chronic spondyloarthropathy in women[24].
Eng et al. demonstrated that carriers of the T allele of this
promotor polymorphism have a higher expression of
both mCD14 and sCD14 and that TNFα production is
increased in the homozygous CD14 -260 T carriers when
stimulated with either C. pneumoniae or C. trachomatis
[25]. In a recent article, Rupp and colleagues described an
Table 1: Patient characteristics in the STD and subfertility cohorts.
STD cohort Subfertility cohort
n 576 253
CT DNA (LCx) + 184
- 392
CT IgG + 217
- 359
CT IgG (MIF) + (> = 32) 41
- (<32) 212
Coinfections - 401
+ 175
C. albicans 160
N. gonorrhoea 7
T. vaginalis 6
H. simplex virus 1 2
H. simplex virus 2 5
Symptoms - 335
+ 221
Vulvovaginal discharge 157
Abdominal pain 81
Dysuria 58
Bleeding during/after coitus 25
Age Average 23.6 y 30 y
Range 15 – 41 y 19 – 39 y
Median 23 y 31 y
Tubal Pathology + 50
- 203
Abbreviations: CT: C. trachomatis; STD: sexually transmitted disease; TP: tubal pathologyPage 3 of 9
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susceptibility to chronic C. pneumoniae infection in coro-
nary artery disease patients[26]. Since the CD14 -260 C>T
is functional[25] and is associated with C. pneumoniae
infection[26], one could hypothesize that in Chlamydia
trachomatis infection this polymorphism could influence
the susceptibility to and severity of this most prevalent
sexually transmitted bacterium which is associated with
female infertility.
Therefore, we investigated the role of the CD14 -260 C>T
polymorphism in the susceptibility to and severity
(defined as subfertility and/or tubal pathology) of C. tra-
chomatis infection in Dutch Caucasian women. A cohort
of women attending a STD clinic was used to assess the
susceptibility to C. trachomatis infection, taking into
account both C. trachomatis DNA and C. trachomatis IgG
detection, symptoms and coinfections. A cohort of subfer-
tile women with or without clinically well-defined tubal
pathology was used to assess the role of CD14 in the sever-
ity of sequelae of C. trachomatis infection.
Methods
Patient populations
STD cohort
Women of Dutch Caucasian (DC) origin (n = 576), under
the age of 33 (range 14 to 33 years; median 22 years) and
visiting the STD outpatient clinic in Amsterdam, The
Netherlands, were included in this study (collection
period: July 2001 – December 2004) (Table 1). All 576
women were consecutively included as the first part of a
large prospective study. For every CT-DNA positive
woman two consecutive CT-DNA negative controls were
included in the study. The women were asked to sign an
informed consent and to fill out a questionnaire, regard-
ing their complaints at that moment, varying from
increased discharge, having bloody discharge during and/
or after coitus, recent abdominal pain (not gastrointesti-
nal or menses related) and/or dysuria. A cervical swab was
taken for the detection of C. trachomatis DNA (CT-DNA)
by PCR (COBAS AMPLICOR; Hoffman – La Roche, Basel,
Switzerland)[27].
Peripheral venous blood was collected for the analysis of
IgG antibodies against C. trachomatis (CT) (Medac Diag-
nostika mbH, Hamburg, Germany). A titre of ≥ 1:50 was
considered positive. Samples with grey zone values, e.g.
cut off ± 10%, were repeated and considered positive
when the result was positive or again within the grey zone.
Infections with the microorganisms: Candida albicans,
Neisseria gonorrhoea, Trichomonas vaginalis, Herpes simplex
virus 1/2, may result in symptoms similar to CT infection.
Infection status for these microorganisms was recorded.
HSV 1/2 was detected according the methods described by
Bruisten et al[28]. N. gonorrhoea was detected according
methods described by Spaargaren et al [29]. T. vaginalis
was cultured on Trichosel medium according standard
procedures [30] and detection of T. vaginalis was accord-
ing the methods described by van der Schee et al [31]. C.
albicans was cultured on Chrom agar and detection of C.
albicans was performed according standard procedures
[30].
Subfertility cohort
The study was performed in 253 consecutive Dutch Cau-
casian women who visited the department of Obstetrics
and Gynaecology of the Academisch Ziekenhuis Maas-
tricht, The Netherlands, between December 1990 and
November 2000 because of subfertility [32]. In these
women a laparoscopy with tubal testing had been per-
formed as part of their fertility work-up. Preoperatively
blood was drawn from all patients for Chlamydia IgG anti-
body testing (CAT), and spare sera were cryopreserved.
Two independent investigators, who were unaware of the
CAT results, scored the laparoscopy reports to assess the
grade of tubal pathology. Tubal pathology was defined as
extensive peri-adnexal adhesions and/or distal occlusion
of at least one tube at laparoscopy [33]. Subfertile women
who had no peri-adnexal adhesions and had patent tubes
at laparoscopy served as negative controls. Based on these
criteria, 50 women had tubal pathology and 203 women
served as controls.
IgG antibodies to C. trachomatis were detected with a spe-
cies-specific MIF test (AniLabSystems, Finland), as
described previously [32], with comparable sensitivity
and specificity as compared to the IgG ELISA from Medac
used for the STD cohort [34]. A positive C. trachomatis IgG
MIF test was defined as a titre ≥1:32. Findings at laparos-
copy were correlated with the MIF test results. Based on
the MIF test, 41 women were found to be CT IgG positive,
while 212 were CT IgG negative. Of the CT IgG positive
women 28 (68.8%) had tubal pathology, while 22
women (10.4%) of the CT IgG negative women had tubal
pathology.
Healthy controls
A healthy Dutch Caucasian control group (n = 170) was
included to assess the general frequency of the CD14 -260
genotypes in the Dutch Caucasian population.
Immunogenetic analyses
DNA Extraction
STD cohort
Eukaryotic DNA from PBMC was isolated using the iso-
propanol isolation method. In short: 100 µl PBMC in PBS
were added to 600 µl L6 (Nuclisens Lysisbuffer, Organon
Teknika, Boxtel, The Netherlands) and 1 µl glycogenPage 4 of 9
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The samples were incubated for 30 minutes at 65°C and
left to cool at RT. An equal volume of cold (-20°C) isopro-
panol was added to the samples. The samples were then
centrifuged (20 min at 20.000 G). The supernatant was
discarded and the pellets were washed twice in 75%
EtOH. The pellets were dissolved in T10 overnight (O/N)
at 4°C and then stored at -20°C until further analysis.
Subfertility cohort
Genomic DNA was extracted out of the cryopreserved sera
using High Pure PCR Template Preparation Kit (HPPTP
kit) according to the manufacturer's instructions (Roche
Molecular Biochemicals, Mannheim, Germany).
Healthy controls
Blood was collected in EDTA-tubes and stored at room
temperature until the genomic DNA was extracted from
peripheral blood leukocytes (PBMC) according to an in-
house DNAzol (Invitrogen, The Netherlands) isolation
procedure.
CD14 -260 C>T gene polymorphism
The C>T substitution in the proximal CD14 promoter GC
box at position -260 from the translation start site (NCBI
SNP CLUSTER ID:rs2569190) results in a HaeIII restric-
tion site. We developed a PCR assay using the primers, 5'
TCA CCT CCC CAC CTC TCT T 3' (sense) and 5' CCT GCA
GAA TCC TTC CTG TT 3' (antisense) (Invitrogen Life
Technologies, Breda, The Netherlands), flanking this
restriction site. Amplification was performed using a ther-
mal cycler Perkin-Elmer 9700 (Applied Biosystems, Forter
City, CA, USA). The parameters were an initial denatura-
tion at 95°C for 5 min, followed by 35 cycles: denatura-
tion at 95°C for 30 s, annealing at 59°C for 30 s, and
elongation at 72°C for 1 min. The final elongation was at
72°C for 7 min followed for a cooling to 4°C. The 107-bp
fragments were digested overnight at 37°C with HaeIII
(Invitrogen, The Netherlands) resulting in fragments that
either were cut in two fragments of 83-bp and 24-bp
(allele C) or were not restricted (T allele). These fragments
were analyzed by electrophoresis on 4% low melting aga-
rose gels (Tebu-Bio, The Netherlands) stained with ethid-
ium bromide.
Statistical analyses
All groups were tested for Hardy-Weinberg equilibrium to
check for Mendelian inheritance. Statistical analyses were
performed using Instat Graphpad and SPSS version 11
(SPSS Inc., Chicago, IL, USA). Fisher exact and χ2 tests
were used to test for differences in CD14 allele/genotype/
carrier frequencies between the (sub)groups and p-values
< 0.05 were considered statistically significant.
Results
All genotype distributions assessed were in Hardy-Wein-
berg Equilibrium. The CD14 -260 C>T SNP was assessed
in the STD, subfertility and control cohorts.
CD14 -260 in the susceptibility to C. trachomatis 
infection
To determine the effects of CD14 -260 C>T on the suscep-
tibility to C. trachomatis infection, the prevalence of CD14
-260 C>T genotypes were assessed in the STD cohort
(table 2). The overall genotype distribution was 28.1%
CC, 50.7% CT, 21.2% TT. This distribution was compara-
ble to the healthy controls (figure 2). The distribution was
28.8% CC, 50.0% CT, 21.2% TT in CT DNA positive
women, while in CT DNA negative women the distribu-
tion was 27.8% CC, 51.0% CT, 21.2% TT. In women with
or without serological CT responses the distribution was
30.4% CC, 49.3% CT, 20.3% TT and 26.7% CC, 51.5%
CT, 21.7% TT, respectively. No differences could be
observed in women with or without symptoms. Coinfec-
tion with other microorganisms or combinations of these
four variables (CT DNA, CT serology, symptoms and
microorganisms) did not introduce statistically significant
differences or trends in CD14 genotype distributions.
CD14 -260 in the severity of sequelae of C. trachomatis 
infection
The effect of CD14 -260 C>T on the severity of sequelae of
C. trachomatis infection was assessed in a cohort of subfer-
tile women with clinically well-defined tubal pathology.
The overall genotype distribution in the cohort was 27.7%
CC, 49.0% CT and 23.3% TT (figure 2). The genotype dis-
tribution in women with tubal pathology was similar to
the distribution in women without tubal pathology
CD14 genotype distribution in the STD, subfertility and con-trol cohortsFigure 2
CD14 genotype distribution in the STD, subfertility 
and control cohorts. Abbreviations: STD: sexually trans-
mitted disease; HC: healthy controlsPage 5 of 9
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CT, 23.2% TT respectively) and to the distribution in the
healthy controls (table 3). Introduction of CT IgG serol-
ogy, with special attention to C. trachomatis positive
women who did develop tubal pathology as compared to
those who did not develop tubal pathology, did not alter
the observed genotype distribution.
Discussion
We did not find an association between the functional
upregulating CD14 -260 C>T polymorphism and the sus-
ceptibility to or subsequent severity of sequelae of C. tra-
chomatis infection, as assessed in the STD and subfertility
populations (figure 2). However, these results do not
exclude that a still unknown CD14 expression decreasing
SNP may influence the course of C. trachomatis infection.
Recent studies have shown that Chlamydia LPS is capable
of inducing an inflammatory response through
CD14[35,36], although the potency to induce an inflam-
matory response was 100 – 1000 times less when com-
pared to the responses induced by S. minnesota, N.
gonorrhoea [35] and the enterobacteria S. enterica and E.
coli[36]. Heine et al. demonstrated that the CD14 associ-
ated inflammatory response was TLR4 but not TLR2 medi-
ated[36]. These results are corroborated by studies
showing the role of the CD14-TLR4-MD2 complex in
intracellular signalling by LPS[13,37] and studies showing
the dependency on CD14 of phagocytosis of Gram nega-
tive bacteria [38].
The absence of an association between CD14 and suscep-
tibility to C. trachomatis infection might be explained by
the compartmentalisation of TLR4. The differential
expression of TLR4 has been described in immortalised
cell-lines derived from the female urogenital tract [39]
and recently demonstrated in cells isolated from patients
by Pioli[40] and Fazeli[41]. TLRs 1 – 6 were found to be
expressed in the epithelia of the female urogenital tract.
TLR2 and TLR4 were the only Toll like receptors with a
clear differential expression. Low expression in the lower
urogenital tract and high expression in the upper genital
tract[40,41]. The expression remained similar in all sub-
jects irrespective of age or status of the reproductive
Table 2: CD14 genotype distribution in the Dutch Caucasian STD cohort.
CD14 -260 C>T
1.1 (CC) 1.2 (CT) 2.2 (TT)
Total n % n % n %
Total 217 66 30,4% 107 49,3% 44 20,3%
CT IgG+ LCx+ (CT DNA+) 135 38 28,1% 69 51,1% 28 20,7%
MO+ 42 12 28,6% 24 57,1% 6 14,3%
Symp 56 14 25,0% 31 55,4% 11 19,6%
LAP+ 17 4 23,5% 10 58,8% 3 17,6%
LCx- (CT DNA-) 82 28 34,1% 38 46,3% 16 19,5%
MO+ 29 12 41,4% 11 37,9% 6 20,7%
Symp 43 16 37,2% 14 32,6% 13 30,2%
LAP+ 17 5 29,4% 8 47,1% 4 23,5%
Total 359 96 26,7% 185 51,5% 78 21,7%
CT IgG- LCx+ (CT DNA+) 49 15 30,6% 23 46,9% 11 22,4%
MO+ 16 3 18,8% 10 62,5% 3 18,8%
Symp 19 5 26,3% 11 57,9% 3 15,8%
LAP+ 10 3 30,0% 6 60,0% 1 10,0%
LCx- (CT DNA-) 310 81 26,1% 162 52,3% 67 21,6%
MO+ 88 20 22,7% 53 60,2% 15 17,0%
Symp 103 26 25,2% 51 49,5% 26 25,2%
LAP+ 37 6 16,2% 20 54,1% 11 29,7%
Healthy Controls 170 48 28,2% 82 48,2% 40 23,5%
C. trachomatis IgG positive and negative patients, divided in CT DNA (LCx) positive and negative and subdivided in coinfection with other 
microorganisms (N. gonorrhoea, T. vaginalis, C. albicans, H. simplex virus 1 & 2), symptoms (vulvovaginal discharge, abdominal pain, dysuria, bleeding 
during/after coitus) and lower abdominal pain. Abbreviations: CT: C. trachomatis; MO+: microorganism positive; LAP+: lower abdominal pain 
positive; Symp: symptoms positivePage 6 of 9
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pattern TLR4 modulates immunological tolerance in the
lower genital tract and induces host defence against
ascending infection in the upper genital tract[41]. In the
upper genital tract, Fazeli and colleagues found TLR4 pos-
itive vacuole like structures that seemed to be secreted
from endocervical glands[42]. A secretory form of TLR4
has been described in mice, where the soluble TLR4
appears to inhibit LPS mediated signals, while at the same
time sTLR4 mRNA is upregulated by LPS[43]. This may
represent a feedback mechanism to prevent excessive
responses to LPS in the endocervix, which can be seen as
a boundary between the lower and upper genital tract.
Further evidence for the regulation of immune responses
to LPS by TLR4 is provided by the study of Harju et al.,
who demonstrated the intrauterine expression of TLR4
and endotoxin responsiveness in mice in the perinatal
period [44]. mCD14 is expressed on human endometrial
stromal cells but not on endometrial epithelial gland
cells. The epithelial cells are dependent on sCD14 for LPS
recognition [45]. Soluble CD14 is present in the cervical
mucosa and may be present in the endometrium[46].
Combining the aforementioned studies with the knowl-
edge that CD14 can signal through TLR4, it might be
hypothesized that the absence of an association between
the CD14 -260 SNP and the susceptibility to C. trachomatis
infection might be due to the low expression or absence of
TLR4 in the lower urogenital tract. In the upper genital
tract, strict regulation of immune responses to LPS by
TLR4 may inhibit CD14 signalling through TLR4 [43,44],
thus limiting the influence of CD14 on the development
of tubal pathology.
However, this hypothesis does not take into account the
ability of CD14 to signal through TLR2[47], nor does it
take into account that the study of Netea et al. which dem-
onstrated that non-LPS components of Chlamydia pneumo-
niae can stimulate cytokine production through TLR2
dependent, CD14 independent pathways[48] and that a
similar mechanism may exist and stimulate C. trachomatis
induced cytokine production in urogenital infections.
Since TLR2 is involved in Chlamydia-induced TGF-beta,
an anti-inflammatory cytokine with an important role in
fibrosis, and thus very likely in post-infection tubal
pathology, it might explain why CD14 polymorphisms
may not severely impact the development of tubal pathol-
ogy[49].
Darville et al. have demonstrated that TLR2 is an impor-
tant mediator of innate immune responses in C. trachom-
atis infection in mice and plays an important role in early
production of immune mediators and development of
tubal pathology[50,51]. In a recent publication by Pitz et
al. it was shown that C. pneumoniae is capable of activating
endothelial cells by TLR2 as initial extracellular C. pneu-
moniae receptor, whereas NOD1 was shown to be a potent
intracellular immune receptor for C. pneumoniae in
endothelial cells. Further research may extend these
results to C. trachomatis infections. Overall, the recogni-
tion of bacterial LPS involves a complex system of multi-
ple receptors and a complex orchestration of protein-
protein interactions [52].
Conclusion
Our study showed that the functional up-regulating CD14
-260 C>T SNP did neither influence the susceptibility to
nor the severity of late sequelae of Chlamydia trachomatis
infection. However, this does not exclude a prominent
role for CD14 in the course of an active C. trachomatis
infection and not yet described CD14 expression decreas-
ing SNPs may affect the course of C. trachomatis infection
profoundly. Further studies on the immunogenetics of C.
trachomatis infection will provide more insight in the clear
differences in the clinical course that this microorganism
induces in individuals and lead to potential vaccine can-
didates.
Table 3: CD14 genotype distribution in the Dutch Caucasian subfertility cohort.
CD14 -260 C>T
1.1 (CC) 1.2 (CT) 2.2 (TT)
Total n % n % n %
Total 253 70 27,7% 124 49,0% 59 23,3%
TP+ 50 14 28,0% 24 48,0% 12 24,0%
TP- 203 56 27,6% 100 49,3% 47 23,2%
CT IgG+ TP+ 28 9 32,1% 15 53,6% 4 14,3%
CT IgG+ TP- 13 4 30,8% 6 46,2% 3 23,1%
Healthy 
Controls
170 48 28,2% 82 48,2% 40 23,5%
Distribution in the total cohort and subdivided in women with or without tubal pathology, and C. trachomatis IgG positive women with or without 
tubal pathology. C. trachomatis positivity defined as a titre ≥ 1:32 (MIF). Abbreviations: TP: tubal pathology; CT: Chlamydia trachomatis.Page 7 of 9
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